The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application for tolebrutinib for the treatment of non-relapsing ...

Sanofi has bolstered the case for its oral BTK inhibitor tolebrutinib as a treatment for multiple sclerosis (MS), due to be filed for approval in the latter half of this year, with new data in a ...

Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three ...

Merck signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion.

The companies… The number of people living with multiple sclerosis (MS ... according to the researchers,… Sanofi’s tolebrutinib significantly delayed disability progression, by 31%, and ...

Four more people with nonactive secondary progressive multiple sclerosis (SPMS ... Treatment with the investigational BTK inhibitor tolebrutinib significantly delayed the onset of confirmed ...

Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney ...

Swiss pharma giant Roche RHHBY faced a setback in its efforts to develop a higher dose of multiple sclerosis drug Ocrevus ...

The Phase III API-CAT trial found that extended anticoagulant therapy with reduced-dose Eliquis (apixaban) was noninferior to ...

Reduction in spleen volume of ≥35% from baseline at week 24 was met in 65.9 and 35.2% of patients randomly assigned to pelabresib-ruxolitinib and placebo-ruxolitinib, respectively. HealthDay ...

is evaluating under priority review the regulatory submission of tolebrutinib to treat non-relapsing secondary progressive multiple sclerosis (nrSPMS) and to slow disability accumulation ...